Xtant Medical Reports Second Quarter 2026 Financial Results
Xtant Medical reported Q2 2026 revenue of $23.0 million, down 35% from $35.4 million in the prior year, resulting in a net loss of $9.4 million compared to net income of $3.6 million. Citing lower-than-expected biologics revenue and headwinds in its advanced wound care market, the company reduced full-year guidance to a range of $99 million to $103 million. Despite the financial shortfall, Xtant launched the Trivium Shaped bone graft product and secured exclusive U.S.
Key figures
- Revenue
- $23.0 million
- Guidance
- $99 million to $103 million (cut from $101 million to $105 million)
- Revenue Yoy
- -35%
- Cash
- $9.9 million
- Ebitda
- -$2.7 million
- Net loss
- $9.4 million
- Gross margin
- 57.9%
- Gross profit
- $13.33 million
- Operating income
- -$9.17 million
- Credit facility availability
- $0.7 million
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.